Axsome Therapeutics (NASDAQ:AXSM - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at Needham & Company LLC in a report issued on Monday,Benzinga reports. They currently have a $133.00 target price on the stock. Needham & Company LLC's price target points to a potential upside of 48.99% from the company's previous close.
A number of other research firms have also weighed in on AXSM. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $121.00 target price on shares of Axsome Therapeutics in a report on Thursday, December 12th. StockNews.com raised shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Royal Bank of Canada raised their price target on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the company an "outperform" rating in a report on Friday, October 4th. Truist Financial upped their price target on shares of Axsome Therapeutics from $150.00 to $180.00 and gave the stock a "buy" rating in a report on Monday. Finally, Mizuho dropped their price objective on Axsome Therapeutics from $124.00 to $122.00 and set an "outperform" rating for the company in a research note on Tuesday, December 31st. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, Axsome Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $129.43.
Check Out Our Latest Stock Report on AXSM
Axsome Therapeutics Stock Performance
Shares of NASDAQ AXSM traded up $9.22 during midday trading on Monday, hitting $89.27. The company's stock had a trading volume of 1,879,139 shares, compared to its average volume of 1,023,747. The stock has a fifty day moving average price of $92.21 and a 200 day moving average price of $89.22. The firm has a market capitalization of $4.33 billion, a price-to-earnings ratio of -13.67 and a beta of 1.04. Axsome Therapeutics has a one year low of $64.11 and a one year high of $105.00. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The business had revenue of $104.76 million for the quarter, compared to analysts' expectations of $98.71 million. During the same quarter in the previous year, the firm posted ($1.32) EPS. On average, research analysts forecast that Axsome Therapeutics will post -4.6 EPS for the current fiscal year.
Institutional Investors Weigh In On Axsome Therapeutics
Hedge funds have recently made changes to their positions in the business. Pallas Capital Advisors LLC purchased a new position in Axsome Therapeutics in the 4th quarter worth $2,237,000. JPMorgan Chase & Co. grew its stake in shares of Axsome Therapeutics by 14.9% during the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock valued at $19,062,000 after buying an additional 27,534 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Axsome Therapeutics by 47.5% in the third quarter. Franklin Resources Inc. now owns 160,534 shares of the company's stock worth $13,713,000 after buying an additional 51,696 shares during the period. Geode Capital Management LLC lifted its stake in shares of Axsome Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 908,459 shares of the company's stock valued at $81,659,000 after acquiring an additional 23,564 shares during the last quarter. Finally, Barclays PLC boosted its holdings in Axsome Therapeutics by 279.6% during the 3rd quarter. Barclays PLC now owns 61,785 shares of the company's stock valued at $5,552,000 after acquiring an additional 45,509 shares during the period. 81.49% of the stock is currently owned by institutional investors.
About Axsome Therapeutics
(
Get Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Recommended Stories
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
